A Phase 2 interventional study of Sodium nitrite and Placebo in Diabetes, sponsored by TheraVasc Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-24.
Sponsored by TheraVasc Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 3,022 studies in Diabetes Mellitus with a site in United States — 289 open to participants now, 389 under way, 12 of them phase 3. Diabetes Mellitus · United States.
Among the 3,022 studies in Diabetes Mellitus with a site in United States, this one is the 1,905th largest by enrollment of the 2,501 interventional ones that give a count, is one of 107 that started in 2015, is one of 279 in phase 2, and was the 1,772nd registered.
8,293 studies on the registry are indexed under Diabetes Mellitus; 1,074 are open to participants now.
Browse Diabetes Mellitus studies →289 of the 3,022 studies in Diabetes Mellitus with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
University of California, Los Angeles · Sites in United States
Ages 18+
Wayne State University · Sites in United States
Ages 16–20
Mayo Clinic · Sites in United States
Ages 18+
Pfizer · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 650 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 197 (30%) stop at 75 or younger; 88 take children under 18; 183 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
3,022 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 262 · Phase 2 371 · Phase 3 340 · Phase 4 215
First in 1976; this study’s year is marked. 107 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 26 is below the median of 80 across 6,024 interventional studies indexed under Diabetes Mellitus.
Median enrollment 82 across the 2,501 interventional studies, 159 across the 499 observational. Of the 2,397 that completed or were terminated, 990 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
852 of 3,022 have an industry lead sponsor. The 10 most frequent:
TheraVasc Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.
TheraVasc Inc. has 1 study filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
139 of the studies in Diabetes Mellitus with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03982693Phase 3Mt. Sinai Medical Center, MiamiTrial to Assess Chelation Therapy in Critical Limb Ischemia | 2026-12 |
| NCT05174052Phase 3University of OklahomaDapagliflozin in Patients With Atrial Fibrillation (DAPA-AF) | 2027-04 |
| NCT02262832Phase 3National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy | 2027-07-31 |
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
| NCT07556354University of Alabama at BirminghamEmpowering Faith-based Communities to Provide Personalized Diabetes Self-management Education and Support (DSMES) in the Magic City | 2026-11 |
Add all 139 to your calendar (.ics) → With an account.
Among the 3,022 studies in Diabetes Mellitus with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In this study, subjects with diabetic neuropathic pain (DNP) will be treated for 12 weeks with either placebo, 40 or 80 mg sustained release sodium nitrite (TV1001sr) twice daily. Primary endpoints will be safety and pharmacokinetics. Assessment of the study medications affects on pain following treatment will also be recorded.
This is a dose-ranging study to evaluate the safety, pharmacokinetics, and tolerability of multiple doses of an oral, sustained release formulation of sodium nitrite (TV1001sr) in subjects with DNP. The primary objective is to assess the safety and tolerability of multiple doses of twice daily 40 mg and 80 mg TV1001sr compared with placebo over a 12 week treatment period and the pharmacokinetics of the sustained release formulation of sodium nitrite. Secondary objectives are to evaluate the pharmacokinetics and markers of functional improvement including pain questionnaires, quantitative sensory testing and changes in markers of diabetes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One placebo tablet administered twice daily for 12 weeks.
Drug: Placebo
One 40 mg enteric coated sustained release, sodium nitrite tablets administered twice daily.
Drug: Sodium nitrite
Two placebo tablets administered twice daily for 12 weeks.
Drug: Placebo
Two 40 mg enteric coated sustained release, sodium nitrite tablets administered twice daily.
Drug: Sodium nitrite
Sustained release formulation of sodium nitrite
Also known as: TV1001sr
Placebo tablets containing same excipients and coatings used in the active tablets, without sodium nitrite being added.
Reporting of Adverse Events During 12 Week Study Period
The primary objective of this clinical study is to evaluate the safety and tolerability of multiple doses of twice daily 40mg and 80mg sustained release sodium nitrite compared with placebo over a 12 week treatment period. The following safety parameters will also be assessed: concomitant medication usage, physical examination, vital signs, Comprehensive Metabolic Panel, and complete blood count. Assessment of acute adverse events (i.e., drop in blood pressure, dizziness) after administration of each dose level. Counts are number of subjects reporting at least 1 Adverse Event. The total Adverse Events recorded in each cohort is also reported.
Time frame: 12 weeks
Pharmacokinetics (Blood Levels of Nitrite)
Blood levels of nitrite will be assessed for 6 hours post-administration on the initial dosing visit.
Time frame: 1 day
The Number of Participants Who Reported Use of Analgesic or Medications for Neuropathic Pain.
Daily patient reported use of analgesic or medications for neuropathic pain. The use of medications were recorded at the baseline visit and during both the intermediate and final visit for each subject. All subjects used at least one prescription pain medication, other than one subject in the 80-mg dose cohort who used only ibuprofen to control pain. Most subjects used more than one prescription pain medication. There was no change in use of pain medications during the trial period.
Time frame: 12 weeks
Assessment of Patients Reported Pain Through Composite Analysis of Pain Questionaires.
Subjects completed the Brief pain inventory (BPI), RAND 36 questionnaire, neuropathic pain symptom inventory (NPSI) and Short Form McGill Pain Questionnaire at each visit for these self-reported questionnaires. The BPI is a questionnaire that measures the patient's subjective perception of pain, its exacerbating and alleviating factors, and perceived effect on functional status; the NPSI is a questionnaire that measures the symptoms associated with neuropathic pain; the Short Form McGill Questionnaire subjectively assesses the patients perception of pain described by commonly used adjectives associated with pain. NPSI is average of 12 questions, range from 0 (no pain) to 120 (maximal pain); For BPI severity and interference, questions are scored from 0-10, then there average score for each subsection is calculated (the higher the score, the worse the response); Scores on McGill range from 0-10, lower associated for less pain, then averaged for each sub score and total score.
Time frame: Baseline (visit 1) and 12 weeks (visit 3)
Clinical Assessment of Pain. (Quantitative Sensory Testing)
Quantitative sensory testing (QST) was conducted at each visit to determine patients sensitivity to pain. QST was assessed using a quantitative nerve conductance machine where nerves in the distal extremity are subjected to electrical stimulation to determine the sensory threshold of the skin. Nerve conductance measures how fast an electrical impulse moves through the nerve, and nerve velocity measures the speed at which an electrical impulse moves down a neuronal pathway.
Time frame: 12 weeks
Assessment of Diabetes. (HbA1C Levels)
HbA1C levels will be monitored at each visit to determine whether treatment reduces circulating glucose levels.
Time frame: 12 weeks
Assessment of Blood Oxygenation. (Pulse Oximetry)
Pulse oximetry will be used at each visit to determine whether treatment improves oxygen levels in the blood.
Time frame: 12 weeks
| Milestone | Placebo | 40 mg TV1001sr | Placebo (2) | 80 mg TV1001sr |
|---|---|---|---|---|
| Started | 4 | 8 | 5 | 9 |
| Completed | 4 | 7 | 5 | 8 |
| Not completed | 0 | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 |
The primary objective of this clinical study is to evaluate the safety and tolerability of multiple doses of twice daily 40mg and 80mg sustained release sodium nitrite compared with placebo over a 12 week treatment period. The following safety parameters will also be assessed: concomitant medication usage, physical examination, vital signs, Comprehensive Metabolic Panel, and complete blood count. Assessment of acute adverse events (i.e., drop in blood pressure, dizziness) after administration of each dose level. Counts are number of subjects reporting at least 1 Adverse Event. The total Adverse Events recorded in each cohort is also reported.
| Adverse Events | Combined Placebo | 40 mg TV1001sr | 80 mg TV1001sr |
|---|---|---|---|
| Subjects reporting at least one Adverse Event | 9 | 8 | 7 |
| Total Adverse Events reported in each cohort | 29 | 23 | 24 |
Blood levels of nitrite will be assessed for 6 hours post-administration on the initial dosing visit.
| ng/ml | Combined Placebo | 40 mg TV1001sr | 80 mg TV1001sr |
|---|---|---|---|
| Pharmacokinetics (Blood Levels of Nitrite) | 1399 ± 47 | 9699 ± 10199 | 9905 ± 12383 |
Daily patient reported use of analgesic or medications for neuropathic pain. The use of medications were recorded at the baseline visit and during both the intermediate and final visit for each subject. All subjects used at least one prescription pain medication, other than one subject in the 80-mg dose cohort who used only ibuprofen to control pain. Most subjects used more than one prescription pain medication. There was no change in use of pain medications during the trial period.
| Participants | Combined Placebo | 40 mg TV1001sr | 80 mg TV1001sr |
|---|---|---|---|
| Subjects using any medicine to treat pain | 9 | 7 | 8 |
| Subjects using Gabapentin | 6 | 6 | 3 |
| Subjects using Lyrica | 4 | 4 | 4 |
| Subjects using Morphine | 2 | 1 | 0 |
| Subjects using Tramadol | 1 | 3 | 3 |
| Subjects using Cymbalta | 1 | 1 | 2 |
| Subjects using Flexeril | 1 | 0 | 2 |
| Subjects using Naproxen | 1 | 3 | 0 |
| Subjects using Percocet | 3 | 1 | 0 |
| Subjects using Vicodin | 2 | 2 | 1 |
Subjects completed the Brief pain inventory (BPI), RAND 36 questionnaire, neuropathic pain symptom inventory (NPSI) and Short Form McGill Pain Questionnaire at each visit for these self-reported questionnaires. The BPI is a questionnaire that measures the patient's subjective perception of pain, its exacerbating and alleviating factors, and perceived effect on functional status; the NPSI is a questionnaire that measures the symptoms associated with neuropathic pain; the Short Form McGill Questionnaire subjectively assesses the patients perception of pain described by commonly used adjectives associated with pain. NPSI is average of 12 questions, range from 0 (no pain) to 120 (maximal pain); For BPI severity and interference, questions are scored from 0-10, then there average score for each subsection is calculated (the higher the score, the worse the response); Scores on McGill range from 0-10, lower associated for less pain, then averaged for each sub score and total score.
| units on a scale | Combined Placebo | 40 mg TV1001sr | 80 mg TV1001sr |
|---|---|---|---|
| NPSI: Total-V1 | 47.4 (7 to 75) | 34.7 (18 to 80) | 56.0 (21 to 83) |
| NPSI: Total-V3 | 43.4 (9 to 81) | 30.0 (0 to 76) | 46.0 (6 to 73) |
| BPI: Severity Score-V1 | 5.1 (1.25 to 7.5) | 4.3 (1.25 to 8.5) | 5.9 (2.5 to 9.3) |
| BPI: Severity Score-V3 | 4.8 (1.5 to 7.8) | 3.8 (0.8 to 8.8) | 5.1 (2.0 to 8.3) |
| BPI: Interferrence-V1 | 5.0 (0.0 to 9.7) | 4.4 (0.7 to 7.9) | 6.4 (2.0 to 8.5) |
| BPI: Interferrence-V3 | 4.3 (0.0 to 10.0) | 4.2 (1.1 to 8.6) | 5.7 (3.1 to 8.9) |
| McGill: Total-V1 | 5.1 (1.1 to 9.1) | 3.9 (1.8 to 7.6) | 4.8 (1.7 to 7.9) |
| McGill: Total-V3 | 3.6 (0.4 to 7.5) | 2.5 (0.5 to 7.2) | 4.6 (0.5 to 7.0) |
| McGill: Continuous-V1 | 5.0 (1.0 to 9.0) | 3.7 (0.9 to 7.2) | 4.4 (0.5 to 8.0) |
| McGill: Continuous-V3 | 3.2 (0.0 to 6.6) | 1.9 (0.0 to 5.8) | 4.3 (0.7 to 7.5) |
| McGill: Intermittent-V1 | 6.0 (0.0 to 9.7) | 4.6 (2.3 to 8.5) | 5.9 (0.3 to 8.0) |
| McGill: Intermittent-V3 | 4.1 (0.0 to 9.2) | 2.8 (0.0 to 8.3) | 5.3 (0.0 to 7.3) |
Quantitative sensory testing (QST) was conducted at each visit to determine patients sensitivity to pain. QST was assessed using a quantitative nerve conductance machine where nerves in the distal extremity are subjected to electrical stimulation to determine the sensory threshold of the skin. Nerve conductance measures how fast an electrical impulse moves through the nerve, and nerve velocity measures the speed at which an electrical impulse moves down a neuronal pathway.
| meters per second | Combined Placebo | 40 mg TV1001sr | 80 mg TV1001sr |
|---|---|---|---|
| Nerve Conductance: Baseline | 3.9 ± 1.4 | 3.4 ± 0.7 | 6.0 ± 2.9 |
| Nerve Conductance: V2 | 4.3 ± 1.8 | 3.1 ± 0.9 | 5.2 ± 3.0 |
| Nerve Conductance: V3 | 3.5 ± 1.2 | 3.2 ± 0.6 | 4.2 ± 1.5 |
| Nerve Velocity: Baseline | 44.7 ± 6.5 | 41.1 ± 4.3 | 39.4 ± 8.2 |
| Nerve Velocity: V2 | 40.1 ± 5.3 | 39.3 ± 7.8 | 42.3 ± 10.7 |
| Nerve Velocity: V3 | 43.2 ± 6.4 | 37.7 ± 3.2 | 46.8 ± 4.2 |
HbA1C levels will be monitored at each visit to determine whether treatment reduces circulating glucose levels.
| percentage of glycosylated hemoglobin | Combined Placebo | 40 mg TV1001sr | 80 mg TV1001sr |
|---|---|---|---|
| Baseline | 7.7 ± 1.4 | 7.7 ± 1.2 | 8.5 ± 2.4 |
| V2 | 7.3 ± 1.2 | 7.4 ± 0.9 | 7.9 ± 1.8 |
| V3 | 7.6 ± 2.0 | 7.7 ± 1.6 | 8.2 ± 1.2 |
Pulse oximetry will be used at each visit to determine whether treatment improves oxygen levels in the blood.
| % Oxygenation | Combined Placebo | 40 mg TV1001sr | 80 mg TV1001sr |
|---|---|---|---|
| Baseline | 95.7 ± 2.6 | 95.6 ± 2.3 | 96.3 ± 1.7 |
| V2 | 96.0 ± 3.0 | 96.4 ± 2.2 | 95.3 ± 3.2 |
| V3 | 94.2 ± 2.8 | 96.0 ± 2.4 | 95.1 ± 2.4 |
Collected over 9 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Combined Placebo | 0/9 (0%) | 2/9 (22.2%) | 9/9 (100%) |
| 40 mg TV1001sr | 0/8 (0%) | 2/8 (25%) | 8/8 (100%) |
| 80 mg TV1001sr | 0/9 (0%) | 2/8 (25%) | 7/9 (77.8%) |
| Event | Combined Placebo | 40 mg TV1001sr | 80 mg TV1001sr |
|---|---|---|---|
| HyponatremiaBlood and lymphatic system disorders | 0/9 | 1/8 | 1/8 |
| HyperglycemiaBlood and lymphatic system disorders | 1/9 | 1/8 | 0/8 |
| Febrile illnessInfections and infestations | 0/9 | 0/8 | 1/8 |
| Chest painsCardiac disorders | 1/9 | 0/8 | 0/8 |
| Event | Combined Placebo | 40 mg TV1001sr | 80 mg TV1001sr |
|---|---|---|---|
| SwellingGeneral disorders | 4/9 | 0/8 | 1/9 |
| Urinary DisordersRenal and urinary disorders | 1/9 | 3/8 | 1/9 |
| DizzinessNervous system disorders | 2/9 | 2/8 | 2/9 |
| ConstipationGastrointestinal disorders | 0/9 | 2/8 | 0/9 |
| HeadachesNervous system disorders | 2/9 | 0/8 | 2/9 |
| NumbnessNervous system disorders | 2/9 | 0/8 | 0/9 |
| UlcersGastrointestinal disorders | 0/9 | 1/8 | 1/9 |
| FatigueNervous system disorders | 1/9 | 1/8 | 0/9 |
| Dry MouthGeneral disorders | 0/9 | 1/8 | 1/9 |
| NauseaGastrointestinal disorders | 1/9 | 1/8 | 0/9 |
| Age, Categorical(Participants) | Placebo | 40 mg TV1001sr | Placebo (2) | 80 mg TV1001sr | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 6 | 2 | 7 | 16 |
| >=65 years | 3 | 2 | 3 | 2 | 10 |
| Sex: Female, Male(Participants) | Placebo | 40 mg TV1001sr | Placebo (2) | 80 mg TV1001sr | Total |
|---|---|---|---|---|---|
| Female | 0 | 3 | 4 | 5 | 12 |
| Male | 4 | 5 | 1 | 4 | 14 |
| Race (NIH/OMB)(Participants) | Placebo | 40 mg TV1001sr | Placebo (2) | 80 mg TV1001sr | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 4 | 8 | 5 | 9 | 26 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Placebo | 40 mg TV1001sr | Placebo (2) | 80 mg TV1001sr | Total |
|---|---|---|---|---|---|
| United States | 4 | 8 | 5 | 9 | 26 |
Plan to share: No — IPD will only be available to the PI of the trial, summary information will be published and shared with other researchers.
No publications or documents are linked to this record.
Ran from Apr 2015 to primary completion in Dec 2015, 7 months.
Results were first posted in Apr 2020, 4 years 4 months after primary completion.
Of 65 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's 7 months is below that.
Counting every sponsor, half of 147 studies reached it within 27 months; a quarter within 12 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sodium Nitrite
TheraVasc Inc.